title: Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
abstract: BACKGROUND
  Information concerning lipid disturbances in HIV-infected women on antiretroviral therapy (ART) is scarce. The objective of the study is to describe the lipid profile in a large cohort of HIV-infected women on contemporary ART and analyse differences between regimes and patient's characteristics.
  
  
  METHODS
  Observational, multicentre, cross-sectional study from the Spanish VACH Cohort. 922 women on stable ART without lipid-lowering treatment were included.
  
  
  RESULTS
  Median age was 42 years, median CD4 lymphocyte count was 544 cells/mm3, and 85.6% presented undetectable HIV-1 viral load. Median total cholesterol (TC) was 189 mg/dL (interquartile range, IQR, 165-221), HDL cholesterol 53 mg/dL (IQR, 44-64), LDL cholesterol 108 mg/dL (IQR, 86-134), and triglycerides 116 mg/dL (IQR, 85-163). Mean accumulated time on ART was 116 months; 47.4% were on NNRTI-based regimes, 44.7% on PI, and 6.7% on only-NRTI therapy. 43.8% were also hepatitis C (HCV) coinfected. Patients on PI treatment presented higher TC/HDL ratio than those on NNRTI (p < 0.001). Significantly higher HDL values were observed in NNRTI-treated patients. HCV-coinfected patients presented lower TC/HDL ratio than the non HCV-coinfected. In multivariate analysis, factors independently associated with TC/HDL ratio were age, triglyceride levels and HCV co-infection. PI treatment presented a non-significant association with higher TC/HDL ratio.
  
  
  CONCLUSIONS
  In HIV-infected women, the NNRTI-based ART is associated with a better lipid profile than the PI-based. Factors unrelated to ART selection may also exert an independent, significant influence on lipids; in particular, age, and triglyceride levels are associated with an increased TC/HDL ratio while HCV co-infection is associated with a reduced TC/HDL ratio.
authors.affiliation: Hospital Clínico San Carlos, Madrid, Spain. vestrada.hcsc@salud.madrid.org
authors.forename: Vicente
authors.initials: V
authors.lastname: Estrada
authors.forename: Paloma
authors.initials: P
authors.lastname: Geijo
authors.forename: Manuel
authors.initials: M
authors.lastname: Fuentes-Ferrer
authors.forename: María Luisa García
authors.initials: ML
authors.lastname: Alcalde
authors.forename: María
authors.initials: M
authors.lastname: Rodrigo
authors.forename: María José
authors.initials: MJ
authors.lastname: Galindo
authors.forename: Agustín
authors.initials: A
authors.lastname: Muñoz
authors.forename: Pere
authors.initials: P
authors.lastname: Domingo
authors.forename: Esteve
authors.initials: E
authors.lastname: Ribera
authors.forename: Jaime
authors.initials: J
authors.lastname: Cosín
authors.forename: Pompeyo
authors.initials: P
authors.lastname: Viciana
authors.forename: Fernando
authors.initials: F
authors.lastname: Lozano
authors.forename: Alberto
authors.initials: A
authors.lastname: Terrón
authors.forename: Antonio
authors.initials: A
authors.lastname: Vergara
authors.forename: Ramón
authors.initials: R
authors.lastname: Teira
authors.forename: Josefa
authors.initials: J
authors.lastname: Muñoz-Sánchez
authors.forename: Bernardino
authors.initials: B
authors.lastname: Roca
authors.forename: Trinitario
authors.initials: T
authors.lastname: Sánchez
authors.forename: José
authors.initials: J
authors.lastname: López-Aldeguer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Deig
authors.forename: Francisco
authors.initials: F
authors.lastname: Vidal
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
authors.forename: Manuel
authors.initials: M
authors.lastname: Castaño-Carracedo
authors.forename: Teresa
authors.initials: T
authors.lastname: Puig
authors.forename: Myriam
authors.initials: M
authors.lastname: Garrido
authors.forename: Ignacio
authors.initials: I
authors.lastname: Suárez-Lozano
mesh_terms: D000328:Adult; D000367:Age Factors; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015992:Body Mass Index; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000097:blood / Q000209:etiology*; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D019370:Observation; D011446:Prospective Studies; D013030:Spain; D014280:Triglycerides / Q000097:blood; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D008076:Cholesterol, HDL; D014280:Triglycerides; D002784:Cholesterol